Want to join the conversation?
$AGN's Namenda XR revenues for 1Q16 were $173MM, as prescriptions and formulary coverage remained stable following the loss of exclusivity of Namenda IR. Lumigan/Ganfort revenues were $170MM reflecting stable performance across its glaucoma product franchise. Bystolic revenues remained stable at $164MM.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.